The phase 3 BOSTON study suggested that a once-per-week combination regimen of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) is an effective treatment option for patients with multiple myeloma who have received 1 to 3 previous lines of therapy.
Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.
This study found that state-level lung cancer screening rates were not aligned with disease burden, with the exception of Kentucky, which has supported comprehensive efforts to implement lung cancer screening.
According to the researchers, the high-quality evidence observed thus far supports the endorsement of this scoring system as a new staging system for prostate cancer.
These results suggested that adolescent and young adult patients treated for acute myeloid leukemia have a high risk of developing long-term health complications.
A study presented at ASTRO suggested that response-based consolidation involved-field radiation therapy appears to be a safe and effective standard of care for a cohort of pediatric patients with high-risk classical Hodgkin lymphoma.
Though researchers found that Black patients with early-stage non-small cell lung cancer are now more likely to receive the most effective treatment compared to a decade ago, the disparity for this patient population persists.
“This might raise the potential of being able to detect disease recurrence much earlier than current clinical practice,” said Thomas Weiland, MD.
Given that diagnosing lung cancer in its early stages can lead to successfully eliminating lung cancer with surgery alone, the importance of closing this disparity gap is critical.
Adagrasib demonstrated an acceptable safety profile and promising clinical activity in pretreated patients with non-small cell lung cancer, colorectal cancer, and other solid tumors with a KRAS G12C mutation.
The latest episode of the journal ONCOLOGY’s podcast features an article published in the November issue discussing fertility preservation and decision-making for young adults with cancer.
Data from a Japanese cohort of patients with primary sclerosing cholangitis suggested ursodeoxycholic acid (UDCA) was significantly associated with reduced mortality or need for liver transplantation and was also likely to be associated with a reduction of biliary tract cancer.
An interim analysis of the trial revealed that among patients with previously untreated advanced ALK-positive non-small cell lung cancer, those who received lorlatinib (Lorbrena) had significantly longer PFS, a higher overall and intracranial response, and better quality of life.
This study demonstrated that clinicians can influence a patient’s recall of medical information provided by using empathy.
Medicaid expansion was found to be associated with improved mortality among patients with newly diagnosed breast, colorectal, and lung cancer.
The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.
The risk of developing testicular cancer may increase with early and repeated exposure to diagnostic imaging, according to a recent study.
Researchers suggested that platinum-based treatment may be considered an option in a biomarker-positive population of patients with advanced prostate cancer with DNA repair gene aberrations.
These study results suggest that osimertinib as adjuvant therapy is an effective treatment strategy for patients with stage IB to IIIA EGFR-positive non-small cell lung cancer following complete tumor resection.
A study presented at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting suggested that ipilimumab (Yervoy) plus nivolumab (Opdivo) for patients with metastatic or unresectable angiosarcoma was well-tolerated.
The SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development.
A study published in American Journal of Preventative Medicine found that expansion of the Affordable Care Act resulted in an increase in early-stage cancer diagnoses and a decrease in late-stage cancer rates for patients.
The FDA has accepted and granted priority review to the biologics license application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
The FDA approved a 1500 mg fixed dose of durvalumab (Imfinzi) administered every 4 weeks for the treatment of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.
Study results suggested that maintenance olaparib (Lynparza) is potentially cost-effective compared with placebo for patients with metastatic pancreatic cancer and a germline BRCA mutation.
According to a survey, nearly 1 in 5 patients with cancer reported that the pandemic would make them less likely to enroll in a clinical trial.
A study published in The BMJ found that even a slight 4-week treatment delay is associated with increased mortality across a number of indications for 7 cancer types.
“In the current era of effective multimodality therapy for breast cancer, the need for [axillary lymph node dissection] for patients with axillary lymph node metastases must be re-evaluated, even for patients with clinically positive nodal disease,” the study authors wrote.
This study found that the increased risk of ovarian cancer in women treated with assisted reproductive technology compared with the general population can likely be explained by nulliparity instead.
The FDA granted fast track designation to rilzabrutinib for the treatment of patients with immune thrombocytopenia.
